Brief: Innate Pharma Says Preclinical Efficacy And Toxicology Data Support Further Development Of IPH45

Innate Pharma SA

10/04/2024 06:06

April 10 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA PRESENTS AT AACR 2024 PRECLINICAL EFFICACY
OF ITS
PRE-IND DRUG CANDIDATE IPH45, A NOVEL NECTIN-4 ANTIBODY DRUG
CONJUGATE
    * IN PDX MODELS OF UROTHELIAL TUMORS, IPH45 HAS STRONGER
ACTIVITY
THAN APPROVED NECTIN-4 TARGETING EV. IPH45 SHOWS ANTI-TUMOR
EFFICACY IN VARIOUS SOLID TUMOR AND EV-REFRACTORY MODELS
    * PRECLINICAL EFFICACY AND TOXICOLOGY DATA SUPPORT FURTHER
DEVELOPMENT OF IPH45 WHICH IS PROGRESSING TOWARDS CLINIC WITH
IND PLANNED IN 2024

Source text for Eikon:  ID:nBw2YZFNMa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))